Hematopoiesis and bone remodeling

Abstract

Erythropoietin (Epo) is a polypeptide hormone produced in kidney. It stimulates the proliferation of erythroid progenitor cells in response to hypoxia. In this issue of Blood, the report of Singbrant et al clearly shows the indirect effect of Epo on bone remodeling and its importance for the Epo-induced erythropoietic response.1 The finding adds a new dimension to the regulatory networks controlling eryropoiesis and bone remodeling.